ARK Space & Defense Innovation ETF vs State Street SPDR S&P Biotech ETF — how do they compare? ARK Space & Defense Innovation ETF trades at $34.71, while State Street SPDR S&P Biotech ETF trades at $159.31. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, ARK Space & Defense Innovation ETF nearer its low. Which is the better fit depends on your goals.
| ARKX | XBI | |
|---|---|---|
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $37.74 | $164.28 |
52-Week Low | $25.46 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Trailing returns across standard periods
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →